Alle Storys
Folgen
Keine Story von Epigenomics AG mehr verpassen.

Epigenomics AG

EANS-News: Epigenomics AG to Update on Clinical Studies with Septin9 Blood Test for Colorectal Cancer at Two Conferences in Europe and the US

BERLIN and SEATTLE - October 22, 2010 (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information/Molecular diagnostics
Epigenomics AG,
the cancer diagnostics company, today announced that it will present 
data from two clinical studies with its proprietary biomarker for the
blood-based detection of colorectal cancer at two conferences in 
Europe and the US during the next week.
The two poster presentations will include data form the recently 
successfully completed prospective PRESEPT Study as well as a 
follow-up study performed to independently validate the diagnostic 
assay that had been used in the PRESEPT Study.
On Tuesday, October 26, 2010, Dr. Juergen Beck, M.D., Senior Vice 
President Medical Affairs at Epigenomics, will present clinical data 
at the 18th United European Gastroenterology Week (UEGW) in 
Barcelona, Spain.
Joseph Romagnuolo M.D., Associate Professor of Medicine in the 
Division of Gastroenterology and Hepatology at the Medical University
of South Carolina will present study data at the American Association
for Cancer Research (AACR) Special Conference "Colorectal Cancer: 
Biology to Therapy" in Philadelphia, PA, USA on Friday, October 29, 
2010.
Prof. Romagnuolo participated as a Clinical Investigator in the 
PRESEPT Study.
Conference Presentation Details
18th United European Gastroenterology Week (UEGW)
October 23-28, 2010
Centre Convencions Internacional Barcelona CCIB, Barcelona, Spain
Poster Presentation: Poster P0990
October 26, 2010, 9 am - 5 pm
AACR Special Conference "Colorectal Cancer: Biology to Therapy"
October 27- 30, 2010
Loews Philadelphia Hotel, Philadelphia, Pennsylvania, USA
Poster Presentation: Poster Session B, Board B29
October 29, 2010, 5 pm - 7 pm
- Ends-
Contact Epigenomics AG:
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368 
pr@epigenomics.com
www.epigenomics.com
Notes to Editors
About Epigenomics
Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation 
biomarkers, Epigenomics´ tests on the market and in development for 
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases thereby potentially 
increasing the patient´s chances of survival.
For development and global commercialization of IVD test products, 
Epigenomics pursues a dual business strategy in which direct 
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with 
broad customer access. Strategic diagnostics industry partners 
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics 
Incorporated, and ARUP Laboratories, Inc. for diagnostics test 
products and services, and QIAGEN N.V. for sample preparation 
solutions and research products.
The company is headquartered in Berlin, Germany, and has a wholly 
owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more 
information, please visit Epigenomics´ website at 
www.epigenomics.com.
Epigenomics´ legal disclaimers. This communication expressly or 
implicitly contains certain forward-looking statements concerning 
Epigenomics AG and its business. Such statements involve certain 
known and unknown risks, uncertainties and other factors which could 
cause the actual results, financial condition, performance or 
achievements of Epigenomics AG to be materially different from any 
future results, performance or achievements expressed or implied by 
such forward-looking statements. Epigenomics AG is providing this 
communication as of this date and does not undertake to update any 
forward- looking statements contained herein as a result of new 
information, future events or otherwise.
The information contained in this communication does not constitute 
nor imply an offer to sell or transfer any product, and no product 
based on this technology is currently available for sale by 
Epigenomics in the United States of America. The analytical and 
clinical performance characteristics of any product based on this 
technology which may be sold at some future time in the USA have not 
been established.
end of announcement                               euro adhoc

Further inquiry note:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Weitere Storys: Epigenomics AG
Weitere Storys: Epigenomics AG